Media Coverage
January 2026 – Fierce Biotech
Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution Read More »
January 2026 – FirstWord Pharma
Immuneering touts 'exceptional' 12-month OS for pancreatic cancer therapy Read More »
January 2026 – Endpoints News
Immuneering’s pancreatic cancer pill continues to beat standard care, updated first line data show Read More »
December 2025 – Clinical Trials Arena
Immuneering progresses MAPK inhibitor in lung and pancreatic cancer Read More »
December 2025 – Rare Cancer News
Pancreatic cancer treatment atebimetinib set for Phase 3 trial Read More »
October 2025 – BioTuesdays
Immuneering outpacing cancer with a novel approach to improving overall survival Read More »
October 2025 – BiotechTV
Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition' Read More »
October 2025 – Let’s Win Pancreatic Cancer
Early nine-month data from a clinical trial suggests a new promising first-line treatment option for patients newly diagnosed with pancreatic cancer. Read More »
October 2025 – Targeted Oncology
Atebimetinib combined with modified gemcitabine/nab-paclitaxel shows remarkable survival rates in first-line pancreatic cancer, surpassing standard treatments. Read More »
October 2025 – OncLive
Atebimetinib Plus Chemo Makes Case As Potential Frontline Option in Pancreatic Cancer Read More »
September 2025 – OncLive
First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer Read More »
September 2025 – Endpoints News
Immuneering builds momentum with additional first-line pancreatic cancer data, aims for Phase 3 this year Read More »
July 2025 – PharmaVoice
The MEK effect on cancer — a slow and steady approach to drug resistance Read More »
June 2025 – Targeted Oncology
Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer Read More »
June 2025 – OncLive
Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer Read More »
June 2025 – Fierce Biotech
Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans Read More »
June 2025 – Cancer Network
Atebimetinib Plus SOC Chemo Improves Survival, Responses in Front-Line PDAC Read More »
Page 1 of 2
